Pharsight

1. Daptomycin patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9655946	HOSPIRA	Daptomycin formulations and uses thereof	Sep, 2033 (9 years from now)
US10357535	HOSPIRA	Daptomycin formulations and uses thereof	Sep, 2033 (9 years from now)

Drugs and Companies using DAPTOMYCIN ingredient

Market Authorisation Date: 21 June, 2021

Treatment: Treatment of complicated skin and skin structure infections and staphylococcus aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis by administering the f...

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
500MG/VIAL	POWDER;INTRAVENOUS	Prescription
350MG/VIAL	POWDER;INTRAVENOUS	Prescription

DAPTOMYCIN family patents

2. Liposyn Iii 30% patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9717852	HOSPIRA	Cartridge holder and pen-type injector	Apr, 2033 (8 years from now)

Drugs and Companies using SOYBEAN OIL ingredient

Market Authorisation Date: 13 January, 1998

Treatment: NA

Dosage: INJECTABLE;INJECTION

Strength	Dosage	Availability
30%	INJECTABLE;INJECTION	Discontinued

LIPOSYN III 30% family patents

3. Precedex patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP12823234A	2019-01-09	Fresenius Kabi Deutschland GmbH	Revoked

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US8242158	March, 2017	Terminated-Denied	Hospira, Inc.	Fresenius Kabi USA, LLC
US8338470	March, 2017	Terminated-Denied	Hospira, Inc.	Fresenius Kabi USA, LLC
US8455527	March, 2017	Terminated-Denied	Hospira, Inc.	Fresenius Kabi USA, LLC
US8648106	August, 2016	Terminated-Denied	Hospira, Inc.	Amneal Pharmaceuticals LLC
US8242158	August, 2016	Terminated-Settled	Hospira, Inc.	Amneal Pharmaceuticals LLC
US8338470	August, 2016	Terminated-Settled	Hospira, Inc.	Amneal Pharmaceuticals LLC
US8455527	August, 2016	Terminated-Settled	Hospira, Inc.	Amneal Pharmaceuticals LLC

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US4910214	HOSPIRA	Optical isomer of an imidazole derivative medetomidine as an alpha-2-receptor agonist	Jul, 2013 (10 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US4910214 (Pediatric)	HOSPIRA	Optical isomer of an imidazole derivative medetomidine as an alpha-2-receptor agonist	Jan, 2014 (10 years ago)
US6716867	HOSPIRA	Use of dexmedetomidine for ICU sedation	Mar, 2019 (5 years ago)
US6716867 (Pediatric)	HOSPIRA	Use of dexmedetomidine for ICU sedation	Oct, 2019 (4 years ago)
US8455527	HOSPIRA	Methods of treatment using a dexmedetomidine premix formulation	Jan, 2032 (7 years from now)
US10016396	HOSPIRA	Dexmedetomidine premix formulation	Jan, 2032 (7 years from now)
US8338470	HOSPIRA	Dexmedetomidine premix formulation	Jan, 2032 (7 years from now)
US8242158	HOSPIRA	Dexmedetomidine premix formulation	Jan, 2032 (7 years from now)
US9616049	HOSPIRA	Dexmedetomidine premix formulation	Jan, 2032 (7 years from now)
US8648106	HOSPIRA	Dexmedetomidine premix formulation	Jan, 2032 (7 years from now)
US9320712	HOSPIRA	Dexmedetomidine premix formulation	Jan, 2032 (7 years from now)
US9616049 (Pediatric)	HOSPIRA	Dexmedetomidine premix formulation	Jul, 2032 (8 years from now)
US8455527 (Pediatric)	HOSPIRA	Methods of treatment using a dexmedetomidine premix formulation	Jul, 2032 (8 years from now)
US8242158 (Pediatric)	HOSPIRA	Dexmedetomidine premix formulation	Jul, 2032 (8 years from now)
US8338470 (Pediatric)	HOSPIRA	Dexmedetomidine premix formulation	Jul, 2032 (8 years from now)
US8648106 (Pediatric)	HOSPIRA	Dexmedetomidine premix formulation	Jul, 2032 (8 years from now)
US9320712 (Pediatric)	HOSPIRA	Dexmedetomidine premix formulation	Jul, 2032 (8 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Dec 16, 2025
New Indication(I-577)	Oct 17, 2011
M(M-61)	Jun 17, 2016
Pediatric Exclusivity(PED)	Dec 17, 2016

Drugs and Companies using DEXMEDETOMIDINE HYDROCHLORIDE ingredient

Market Authorisation Date: 31 January, 2020

Treatment: Intensive care unit sedation, including sedation of non-intubated patients prior to and/or during surgical and other procedures; Use for sedation